Episode description
GLP-1 drugs, like Ozempic, Wegovy, and Zepbound, have gained attention for their significant health impacts and anti-obesity effects. However, there continues to be a lot of unknowns surrounding these medications, their long-term impacts, and access.
Featuring: Dr. Lydia Alexander, an obesity medicine specialist, lifestyle specialist, president of the Obesity Medicine Association (OMA), Chief Medical Officer at Enara, and a medical chef.
In today’s episode, we’ll cover
- The significant progress made in GLP-1 research, care delivery, and insurance coverage
- Filling research gaps in GLP-1 care through longitudinal studies examining long-term medication effects and potential adverse reactions
- Tips for providers managing patients on GLP-1 medications and patient-focused approaches to obesity management
And more!
To watch video clips from our podcast, subscribe to our YouTube channel, @Healthcare Strategies
Resources: